{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:08:37Z","timestamp":1784041717795,"version":"3.55.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ctrv.2026.103176","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:22:44Z","timestamp":1782170564000},"page":"103176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Precision targeting of CLDN18.2: A new therapeutic paradigm for gastric cancer"],"prefix":"10.1016","volume":"148","author":[{"given":"Wei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuxuan","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changchun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103176_bb0005","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/cac2.70017","article-title":"Global trends and epidemiological shifts in gastrointestinal cancers: insights from the past four decades","volume":"45","author":"Li","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.ctrv.2026.103176_bb0010","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2026.103176_bb0015","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(25)00052-2","article-title":"Gastric cancer","volume":"405","author":"Sundar","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103176_bb0020","doi-asserted-by":"crossref","first-page":"912","DOI":"10.21147\/j.issn.1000-9604.2025.06.04","article-title":"Cancer statistics in China: epidemiology, risk factors, and prevention","volume":"37","author":"Cao","year":"2025","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103176_bb0025","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2026.103176_bb0030","first-page":"212","article-title":"Advances and challenges in gastric cancer testing: the role of biomarkers","volume":"22","author":"Sun","year":"2025","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.ctrv.2026.103176_bb0035","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41571-026-01134-1","article-title":"Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics","volume":"23","author":"Choo","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0040","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO-25-02958","article-title":"Immunotherapy and targeted therapy for advanced gastroesophageal Cancer: ASCO guideline update","volume":"44","author":"Shah","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0045","doi-asserted-by":"crossref","first-page":"127","DOI":"10.5230\/jgc.2026.26.e10","article-title":"CLDN18.2 in gastric Cancer: current therapeutic landscape and future perspectives","volume":"26","author":"Zhang","year":"2026","journal-title":"J Gastric Cancer"},{"key":"10.1016\/j.ctrv.2026.103176_bb0050","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-026-01803-9","article-title":"Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies","volume":"19","author":"Xie","year":"2026","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17233764","article-title":"CLDN18.2-targeted therapy in gastrointestinal cancers","volume":"17","author":"Dominguez Wiscovitch","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103176_bb0060","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","article-title":"Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Shitara","year":"2024","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctrv.2026.103176_bb0065","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103176_bb0070","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103176_bb0075","doi-asserted-by":"crossref","first-page":"S895","DOI":"10.1016\/j.annonc.2024.08.1504","volume":"35","author":"Kang","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0080","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41568-026-00913-3","article-title":"Claudin proteins as emerging therapeutic targets for solid tumours","volume":"26","author":"Saviano","year":"2026","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2026.103176_bb0085","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0090","article-title":"Zolbetuximab+ CAPOX in 1L claudin-18.2+(CLDN18. 2+)\/HER2\u2212 locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma: primary phase 3 results from GLOW","volume":"41","author":"Xu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0095","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1200\/JCO.2024.42.16_suppl.4036","volume":"42","author":"Shitara","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS504","volume":"43","author":"Okunaka","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0105","article-title":"P93-2 randomized phase II study of fixed dose of zolbetuximab for CLDN18. 2-positive mGC\/GEJC (GENTLE-Z)","volume":"36","author":"MJAOO","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0110","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1038\/s41591-026-04306-9","article-title":"First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial","volume":"32","author":"Shitara","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103176_bb0115","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.2_suppl.LBA284","article-title":"Phase 2 ILUSTRO trial of 1L zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18. 2+ locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma","volume":"44","author":"Shitara","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.2_suppl.TPS473","article-title":"Zolbetuximab+ pembrolizumab and chemotherapy as first-line treatment for patients with CLDN18. 2-positive, HER2-negative, PD-L1-positive locally advanced unresectable or metastatic G\/GEJ adenocarcinoma: phase 3, double-blind, randomized trial (LUCERNA)","volume":"44","author":"Shitara","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0125","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1200\/JCO.2023.41.4_suppl.397","article-title":"A phase I\/II study of ASKB589 (anti-claudin 18.2 [CLDN18. 2] monoclonal antibody) in patients with solid tumors","volume":"41","author":"Zhang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0130","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2024.42.3_suppl.317","article-title":"A phase Ib\/II study of ASKB589 (anti-Claudin 18.2 [CLDN18. 2] monoclonal antibody) combined with CAPOX and PD-1 inhibitor as first-line treatment for locally advanced, relapsed and metastatic gastric\/gastro-esophageal junction (G\/GEJ) adenocarcinoma","volume":"42","author":"Peng","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0135","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2025.43.4_suppl.454","article-title":"Updated efficacy results of ASKB589 combined with CAPOX and PD-1 inhibitor as first-line treatment for metastatic gastric\/gastro-esophageal junction (G\/GEJ) adenocarcinoma from a phase Ib\/II study","volume":"43","author":"Peng","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0140","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.2024.42.16_suppl.4049","article-title":"Safety and efficacy results from the phase I\/IIa study of FG-M108 plus CAPOX as first-line (1L) treatment for patients with CLDN18. 2+\/HER2-locally advanced unresectable or metastatic gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma","volume":"42","author":"Liu","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0145","doi-asserted-by":"crossref","first-page":"S892","DOI":"10.1016\/j.annonc.2024.08.1499","article-title":"1433P a phase I\/II study of FG-M108 plus capecitabine and oxaliplatin (CAPOX) as first-line (1L) treatment for patients with CLDN18. 2+\/HER2-advanced gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma","volume":"35","author":"Gong","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0150","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2025.43.4_suppl.431","article-title":"FG-M108 plus capecitabine and oxaliplatin (CAPOX) for first-line treatment of CLDN18. 2+\/HER2-advanced gastric\/gastroesophageal junction adenocarcinoma (GC): update results of a phase I\/II trial to determine RP2D","volume":"43","author":"LJJoCO","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0155","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-CT132","volume":"84","author":"Janjigian","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103176_bb0160","doi-asserted-by":"crossref","first-page":"S885","DOI":"10.1016\/j.annonc.2024.08.1485","article-title":"1419P Osemitamab (TST001) plus nivolumab and CAPOX as the first-line therapy for the patients with advanced G\/GEJ cancer (TranStar102)","volume":"35","author":"Shen","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0165","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2025.43.16_suppl.4032","article-title":"First-line osemitamab (TST001) plus nivolumab and CAPOX for advanced G\/GEJ cancer (TranStar102): updated results of cohort G from a phase I\/IIa study","volume":"43","author":"Gong","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0170","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1200\/JCO.2022.40.16_suppl.3086","article-title":"Safety, tolerability, pharmacokinetics and preliminary efficacy of MIL93, an anti-Claudin18. 2 monoclonal antibody, in patients with advanced solid tumors: a phase 1 clinical study","volume":"40","author":"Huang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0175","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2023.41.4_suppl.798","article-title":"Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: the monotherapy part of a phase 1 trial","volume":"41","author":"Huang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0180","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1200\/JCO.2023.41.4_suppl.391","article-title":"A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18. 2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0185","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006704","article-title":"CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation","volume":"11","author":"Gao","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103176_bb0190","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1158\/1078-0432.CCR-24-4280","article-title":"A first-in-human study of Givastomig, a CLDN18.2 and 4-1BB bispecific antibody, as monotherapy in patients with CLDN18.2-positive advanced or metastatic solid tumors","volume":"31","author":"Ku","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103176_bb0195","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/j.annonc.2025.05.404","article-title":"388MO preliminary safety and efficacy of givastomig, a novel claudin 18.2\/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in metastatic gastroesophageal carcinoma (mGEC)","volume":"36","author":"Klempner","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0200","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1158\/1538-7445.AM2022-5551","article-title":"Abstract 5551: QLS31905, an anti-claudin 18.2\/CD3 bispecific antibody for claudin 18.2-positive gastric cancer","volume":"82","author":"Jiang","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103176_bb0205","article-title":"132P a phase I clinical trial of QLS31905 in advanced solid tumors","volume":"20","author":"Wang","year":"2023","journal-title":"Immuno-Oncol Technol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0210","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.2025.43.16_suppl.2527","article-title":"Safety and efficacy of QLS31905 in patients with advanced solid tumors: updated data from phase 1 study","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0215","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-025-04597-8","article-title":"Safety and preliminary efficacy results of IBI389, an anti-Claudin18. 2\u00d7 CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study","volume":"24","author":"Li","year":"2026","journal-title":"BMC Med"},{"key":"10.1016\/j.ctrv.2026.103176_bb0220","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2022.40.16_suppl.2568","article-title":"Safety results of Q-1802, a Claudin18. 2\/PD-L1 bsABs, in patients with relapsed or refractory solid tumors in a phase 1 study","volume":"40","author":"Gong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0225","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1200\/JCO.2023.41.4_suppl.382","article-title":"Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18. 2\/PD-L1 bsABs, in patients with relapsed or refractory solid tumors","volume":"41","author":"Yk","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0230","first-page":"A1729","article-title":"1500 a phase II trial of bispecific antibody Q-1802 in patients with relapsed or refractory solid tumors","volume":"12","author":"Wang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103176_bb0235","article-title":"544 a phase I\/II clinical trial of anti-CLDN18. 2\/PD-L1 recombinant humanized bispecific antibody Q-1802 combined with XELOX chemotherapy in untreated advanced GC\/GEJ patients","volume":"13","author":"Wang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103176_bb0240","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1158\/1538-7445.AM2023-2962","article-title":"ASP2138, a novel 2+ 1 format, claudin 18.2 x CD3 bispecific antibody, demonstrates selectivity and activity in preclinical cancer models","volume":"83","author":"Nakazawa","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103176_bb0245","doi-asserted-by":"crossref","first-page":"S1121","DOI":"10.1016\/j.annonc.2025.08.2756","article-title":"2137P ASP2138 monotherapy in patients (pts) with claudin 18 isoform 2 (CLDN18. 2)+, advanced solid tumors: phase I\/Ib trial","volume":"36","author":"Shitara","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0250","doi-asserted-by":"crossref","first-page":"S1120","DOI":"10.1016\/j.annonc.2025.08.2755","volume":"36","author":"Dayyani","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fmmed.2025.1661016","article-title":"Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules","volume":"5","author":"Katoh","year":"2025","journal-title":"Front Mol Med"},{"key":"10.1016\/j.ctrv.2026.103176_bb0260","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/j.annonc.2024.05.311","article-title":"396MO anti-claudin 18.2 (CLDN18. 2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric\/gastro-esophageal junction adenocarcinoma (G\/GEJ AC): a phase I study","volume":"35","author":"Liu","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0265","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","article-title":"CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial","volume":"31","author":"Liu","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103176_bb0270","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4201","article-title":"A multiregional, randomized, controlled, open-label, phase 3 study of the anti-claudin18. 2 (CLDN18. 2) antibody-drug conjugate (ADC) arcotatug tavatecan (IBI343) in gastric or gastroesophageal junction adenocarcinoma (G\/GEJA): trial in progress","volume":"43","author":"Shen","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0275","article-title":"CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors","volume":"5","author":"Xu","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ctrv.2026.103176_bb0280","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.36_suppl.434420","article-title":"A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant\/refractory solid tumors","volume":"41","author":"Xu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0285","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","article-title":"Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial","volume":"26","author":"Ruan","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0290","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1200\/JCO.2026.44.16_suppl.4023","article-title":"Sonesitatug vedotin (Sone-Ve) monotherapy in patients (pts) with claudin 18.2\u2013positive (CLDN18. 2+) advanced or metastatic gastric or gastroesophageal junction (GEJ) cancers: Data from CLARITY-PanTumor01","volume":"44","author":"Shitara","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0295","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1200\/JCO.2024.42.16_suppl.3028","article-title":"A phase 1\/2 study of LM-302, an anti-claudin 18.2 (CLDN18. 2) antibody-drug conjugate in patients with advanced gastric\/gastroesophageal junction cancer","volume":"42","author":"Bai","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115808","article-title":"Tecotabart vedotin in Claudin 18.2-positive advanced gastric\/gastroesophageal junction cancer: a Bayesian phase 1\/2 clinical trial","volume":"230","author":"Bai","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103176_bb0305","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1200\/JCO.2025.43.16_suppl.4039","article-title":"Efficacy and safety of LM-302 (anti-claudin 18.2 ADC) in combination with anti-PD-1 therapy for advanced gastric, gastroesophageal junction cancer and esophageal adenocarcinoma: early-phase study results","volume":"43","author":"Jiang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0310","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1016\/j.annonc.2024.08.676","article-title":"609O CLDN18. 2 targeted antibody-drug conjugate (ADC), SHR-A1904, in patients (pts) with gastric\/gastroesophageal junction cancer (GC\/GEJC): a phase I study","volume":"35","author":"Xu","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0315","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1038\/s41591-025-03781-w","article-title":"The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial","volume":"31","author":"Ruan","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103176_bb0320","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1200\/JCO.2025.43.16_suppl.3026","article-title":"First in human phase I study of TQB2103, a Claudin18. 2 (CLDN18. 2) targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors","volume":"43","author":"Cheng","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0325","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2026-1690","article-title":"Preclinical development of XNW27011, an antibody drug conjugate targeting claudin18. 2 for treatment of CLDN 18.2-positive solid tumors","volume":"86","author":"Hu","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103176_bb0330","doi-asserted-by":"crossref","first-page":"S514","DOI":"10.1016\/j.annonc.2024.08.717","article-title":"651P phase I study of XNW27011, a novel claudin 18.2 ADC, in patients with locally advanced and\/or metastatic solid tumors","volume":"35","author":"Yu","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0335","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.2025.43.16_suppl.3034","article-title":"Efficacy and safety of XNW27011, a Claudin 18.2 targeting antibody drug conjugate with topoisomerase 1 inhibitor payload, in patients with Claudin 18.2 positive gastric\/gastroesophageal junction cancer: results from ongoing phase I\/II study","volume":"43","author":"Yu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0340","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT010","article-title":"Abstract CT010: phase I dose-escalation and expansion study of JS107, a claudin 18.2 (CLDN18. 2)-targeting antibody-drug conjugate (ADC), as monotherapy or in combination for patients (pts) with advanced solid tumors","volume":"85","author":"Xu","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103176_bb0345","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.1005693","volume":"36","author":"Xu","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0350","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1158\/1538-7445.AM2026-5643","article-title":"Preclinical characterization of RC118 ADC and identification of its differential binding pattern relative to other anti-CLDN18. 2 antibodies","volume":"86","author":"Wang","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103176_bb0355","doi-asserted-by":"crossref","first-page":"S903","DOI":"10.1016\/j.annonc.2024.08.1522","article-title":"1456P first in human phase I\/II trial of claudin 18.2 ADC RC118 in patients with advanced gastric\/gastroesophageal junction cancer","volume":"35","author":"Liu","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0360","doi-asserted-by":"crossref","first-page":"S1625","DOI":"10.1016\/j.annonc.2025.09.098","article-title":"LBA83 RC118 (CLDN18. 2-targeted ADC) combined with PD-1 blockade or RC148 (PD-1\/VEGF bispecific antibody) for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma (la\/m G\/GEJA)","volume":"36","author":"Yu","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0365","doi-asserted-by":"crossref","first-page":"S1122","DOI":"10.1016\/j.annonc.2025.08.2758","article-title":"2139P SKB315, a novel claudin 18.2 (CLDN18. 2) antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors including gastric\/gastroesophageal junction cancer (GC\/GEJC): a phase I study","volume":"36","author":"Deng","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0370","article-title":"ATG-022, an antibody-drug conjugate targeting Claudin 18.2, demonstrated potent in vivo efficacy in gastric cancer patient-derived xenografts","volume":"82","author":"Chen","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103176_bb0375","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2024.42.16_suppl.3032","article-title":"An open-label, multicenter, phase I study of ATG-022 in patients with advanced\/metastatic solid tumors (CLINCH)","volume":"42","author":"Bishnoi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0380","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2025.43.4_suppl.456","article-title":"Safety and preliminary efficacy of ATG-022 in patients with advanced\/metastatic gastric cancer (CLINCH)","volume":"43","author":"Ma","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0385","doi-asserted-by":"crossref","first-page":"S1111","DOI":"10.1016\/j.annonc.2025.08.2733","article-title":"2113P phase I\/II study of claudin 18.2 ADC ATG-022 in patients with advanced gastric\/gastroesophageal junction cancer (CLINCH)","volume":"36","author":"Ma","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0390","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-471716","article-title":"Cell-based therapies in GI cancers: current landscape and future directions","volume":"45","author":"Nakayama","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ctrv.2026.103176_bb0395","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(25)01095-5","article-title":"CAR T-cell therapy in advanced gastro-oesophageal cancer","volume":"405","author":"Ghidini","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103176_bb0400","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103176_bb0405","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1200\/JCO.2024.42.16_suppl.2501","article-title":"Claudin18. 2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: final results of CT041-CG4006 phase 1 trial","volume":"42","author":"Qi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0410","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2025.43.16_suppl.4015","article-title":"Decoding the response and resistant features to the Claudin18. 2-specific CAR-T cell CT041 in gastric cancer: a multi-omics exploratory biomarker analysis of the phase 1 clinical trial","volume":"43","author":"Peng","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0415","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.2024.42.3_suppl.356","article-title":"CLDN18. 2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: results of ELIMYN18. 2 phase 1b clinical trial","volume":"42","author":"Botta","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0420","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007927","article-title":"Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells","volume":"12","author":"Botta","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103176_bb0425","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103176_bb0430","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2025.43.16_suppl.4003","article-title":"Claudin18. 2-specific CAR T cells (Satri-cel) versus treatment of physician\u2019s choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G\/GEJC): primary results from a randomized, open-label, phase II trial (CT041-ST-01)","volume":"43","author":"Qi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0435","doi-asserted-by":"crossref","first-page":"e16012","DOI":"10.1200\/JCO.2024.42.16_suppl.e16012","article-title":"Outstanding safety and efficacy data of IMC002, an autologous CLDN18. 2-targeting CAR-T, in CLDN18. 2+ advanced solid tumors","volume":"42","author":"Luo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0440","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2026.44.2_suppl.398","article-title":"Phase I trial of efficacy and safety of IMC002, a VHH-based anti-CLDN18. 2 CAR-T therapy, for gastroesophageal cancers","volume":"44","author":"Li","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0445","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2025.43.16_suppl.4022","article-title":"Preliminary results of a phase 1 study of LB1908, an autologous Claudin 18.2\u2013targeted chimeric antigen receptor T-cell product, in patients with advanced gastroesophageal adenocarcinoma","volume":"43","author":"Zhen","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0450","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1200\/JCO.2026.44.2_suppl.374","article-title":"Phase 1 study of LB1908, an autologous claudin 18.2-targeted CAR-T cell product, in subjects with advanced gastroesophageal adenocarcinoma","volume":"44","author":"Zhen","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0455","article-title":"Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer","volume":"9","author":"Yamamoto","year":"2025","journal-title":"ESMO Gastrointest Oncol"},{"key":"10.1016\/j.ctrv.2026.103176_bb0460","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s10120-025-01703-w","article-title":"Antibody-drug conjugates in gastric cancer: clinical advances and resistance mechanisms","volume":"29","author":"Li","year":"2026","journal-title":"Gastric Cancer"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:45:57Z","timestamp":1784040357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":92,"alternative-id":["S0305737226000903"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103176","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision targeting of CLDN18.2: A new therapeutic paradigm for gastric cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103176"}}